The function of the Bioinformatics and Data Management Core is to provide the informatics infrastructure, analysis tools and specialized expertise required to support the complex data analysis, integration and storage needs of this Projects and Cores of this grant. Led by Dr. Sarah Cooley, Director of the Masonic Cancer Center Oncology Medical Informatics & Services (OMIS) shared resource, it is composed of two teams providing bioinformatics (UK Team; Anthony Nolan Research Institute) and clinical research data management support (MN team: OMIS). The two groups will meet in person annually and have teleconferences at least every 4 months to ensure the efficient and integrated management of the Core. The MN team is responsible for the development and maintenance of database applications to collect, integrate and report research data generated by the projects for subsequent analysis. In addition they will support and customize the clinical trials management applications to meet the research and regulatory data requirements for the complex (phase I, IND, multi-center) trials in Project 3. The sharing of research samples processed and analyzed by Core D will be coordinated through this Core with a customized sample inventory management tool. Lastly, this team will ensure data quality, data integrity, and data sharing, in compliance with HIPAA regulation and NIH principles. The UK Team will provide bioinformatics support by developing the IPD-KIR Database which will facilitate the work of both the global research community and the grant members. They will continue to collect and curate the KIR sequence data and provide regular updates of this data to allow further development of the typing and sequencing strategies for KIR determination. These developments will include custom bioinformatics tools and applications specifically designed to aid research by other grant members. An expanded suite of bespoke analysis tools will be imbedded to allow advanced analysis for non- Bioinformaticians. A key aim of the IPD project is to provide high quality data that can easily be retrieved and used by non-Bioinformaticians. This can be seen in the work of the IMGT/HLA Database where high level data files, XML, are available for Bioinformaticians, but also tools with easy to use interfaces are provided to allow data analysis possible for a wider range of researchers. They will fully characterize novel KIR sequences detected in Project 1 (SA3) and ensure these data are represented in the public database this will be achieved by conventional cloning methodologies and employing third generation sequencing strategies on the Pacific Biosciences RS II platform. The scientific expertise provided by this team will be invaluable to analyze and interpret immunogenetic data.

Public Health Relevance

This Program Project Grant, which includes four clinical trials and multiple laboratory-based research studies, will generate significant amounts of complex data from multiple sites, all of which must be integrated for definitive analysis. This Core contains Faculty and staff at the University of Minnesota and from the Anthony Nolan Research Institute to develop and support the requisite informatics tools and infrastructure to facilitate sample and data sharing and data analysis to support the basic, translational and clinical research aims.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA111412-11A1
Application #
8998774
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2004-12-01
Project End
2021-03-31
Budget Start
2016-04-05
Budget End
2017-03-31
Support Year
11
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Grzywacz, Bartosz; Moench, Laura; McKenna Jr, David et al. (2018) Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. J Immunother :
Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2018) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant 24:618-622
Don Yun, Hyun; Felices, Martin; Vallera, Daniel A et al. (2018) Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv 2:1580-1584
Cooley, Sarah; Parham, Peter; Miller, Jeffrey S (2018) Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood 131:1053-1062
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527
Oh, Felix; Todhunter, Deborah; Taras, Elizabeth et al. (2018) Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin. Clin Pharmacol 10:113-121
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494

Showing the most recent 10 out of 108 publications